FDA grants orphan drug designation for SK Biopharmaceuticals carisbamate
Carisbamate has previously been shown to have efficacy in trials for adult forms of epilepsy, such as partial onset seizures. IS is a form of epilepsy associated with
US-based gene therapy biotech Seawolf Therapeutics and Sanofi have signed a multi-target research partnership and exclusive licensing deal worth up to $1.2bn to develop treatments for bleeding disorders and other undisclosed indications.